ArticleJournal of neuro-oncology2016
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- The effects of chemotherapy on brain regions: implications for chemobrain revealed through metabolomic profiling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma.Frontiers in oncology · 2026Article
- Synthesis, Cytotoxicity, and Mechanistic Evaluation of Tetrahydrocurcumin-Amino Acid Conjugates as LAT1-Targeting Anticancer Agents in C6 Glioma Cells.International journal of molecular sciences · 2024Article
- Article
- Epilepsy in Patients with Gliomas.Neurologia medico-chirurgica · 2024Review
- The Temozolomide-Doxorubicin paradox in Glioblastoma in vitro-in silico preclinical drug-screening.Scientific reports · 2024Article
- Research progress of anti-glioma chemotherapeutic drugs (Review).Oncology reports · 2022Review
- Mifepristone Repurposing in Treatment of High-Grade Gliomas.Frontiers in oncology · 2021Review
- Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme.Nanoscale advances · 2020Article
- Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors.Nanoscale · 2019Article
- Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma.Oncotarget · 2018Article
- Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.Molecular neurobiology · 2018Article
- Glycosylation Changes in Brain Cancer.ACS chemical neuroscience · 2018Review
- Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24h in a rat 9L gliosarcoma model.Magnetic resonance imaging · 2017Article
- Reversal of doxorubicin-resistance byOncology letters · 2017Article
- Combined Effects of Doxorubicin and Temozolomide in Cultured Glioblastoma Cells.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temozolomide is a standard chemotherapy agent for malignant gliomas, but the efficacy is still not satisfactory. Therefore, combination chemotherapy using temozolomide with other anti-tumor compounds is now under investigation. Here we studied the mechanism of the synergistic anti-tumor effect achieved by temozolomide and doxorubicin, and elucidated the inhibitory effect of temozolomide on P-glycoprotein (P-gp). Temozolomide significantly enhanced sensitivity to P-gp substrate in glioma cells, particularly in P-gp-overexpressed cells. Synergetic effects, as determined by isobologram analysis, were observed by combining temozolomide and doxorubicin. Subsequently, flow cytometry was utilized to assess the intracellular retention of doxorubicin in cells treated with doxorubicin with or without temozolomide. Temozolomide significantly increased the accumulation of doxorubicin in these cells. The P-gp adenosine triphosphatase (ATPase) assay showed that temozolomide inhibited the ATPase activity of P-gp. In addition, temozolomide combined with doxorubicin significantly prolonged the survival of 9L intracranial allografted glioma-bearing rats compared to single agent treatment. Collectively, our findings suggest that temozolomide can reverse doxorubicin resistance by directly affecting P-gp transport activity. Combination chemotherapy using temozolomide with other agents may be effective against gliomas in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.